IRVINE, Calif., July 19, 2012 /PRNewswire/ -- ChromaDex® Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, and marketer of its branded, patented pterostilbene, pTeroPure®, announced today a distribution agreement for pTeroPure with Glanbia Nutritionals (NA), Inc., a global ingredient and micronutrient premix company. Under the terms of the agreement, Glanbia Nutritionals will serve as the exclusive distributor of pTeroPure in North America to the food, beverage and dietary supplement industries.
Pterostilbene is an antioxidant found in blueberries and other berries and believed by many experts to have a number of health benefits. Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other antioxidant polyphenols (substances from plants that tend to prevent or neutralize the damaging effects of free radicals). pTeroPure pterostilbene was named as the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan.
Along with a number of other effects, pterostilbene has shown to support heart health, cognitive function and anti-aging. Data from the first human clinical trial of pTeroPure pterostilbene showed the compound to be generally safe for human consumption. The safety results were presented at the 6th World Congress on Polyphenols Applications in Paris, France on June 7, 2012.(i) Data analyses from the trial on the effects of pTeroPure on blood pressure, triglycerides, cholesterol and oxidative stress are currently underway, and results are expected to be made public following acceptance in a peer-reviewed journal.
"As an innovative ingredient with impressive scientific support, pTeroPure is an excellent addition to our current product line," said Richard Hazel, CEO of Glanbia Nutritionals. "We're excited to work with ChromaDex to increase their current market presence and introduce pTeroPure into new applications and territories."
Commenting on the announcement, Frank Jaksch, CEO and Founder of ChromaDex, stated, "We are looking forward to the national expansion of pTeroPure and its adoption into numerous consumer products. Glanbia, together with its superb sales, marketing and R&D teams, is an ideal partner for ChromaDex. With our recently announced pTeroPure clinical safety results and the forthcoming human efficacy data, Glanbia should be well positioned to bring our exciting novel patented and proven ingredient to the food & beverage, dietary supplement, and animal health markets."
About Glanbia Nutritionals (NA), Inc.:
Glanbia Nutritionals is a division of Glanbia plc, an international nutritional solutions and cheese group, headquartered in Kilkenny, Ireland. The Group has 4,300 employees worldwide, with operations in Ireland, the UK, Germany, USA, Canada, Mexico and China, as well as strategic international joint ventures in the UK, USA and Nigeria. Glanbia is listed on both the Dublin and London Stock Exchange. Glanbia is a global supplier of nutritional ingredients, functional ingredients and customized premix solutions. Glanbia Nutritionals is on the forefront in the exploration of science and the dynamics that drive the growing nutrition industry. For more information visit www.glanbianutritionals.com or contact Thomas Monroe, Marketing, 760-438-0089, firstname.lastname@example.org.
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products include patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40% cyanidin-3-glucoside and is in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property.
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
(i) McEwen CL. Analysis of safety from a human clinical trial with pterostilbene. Poster presentation at: International Society of Antioxidants in Nutrition and Health (ISANH) 6th World Congress on Polyphenols Applications: Paris Polyphenols 2012. June 7-8, 2012, Paris France.
ChromaDex Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
Alex Partners, LLC
Scott Wilfong, President
ChromaDex pTeroPure® Contact:
SOURCE ChromaDex Corporation